Imricor Medical Systems is advancing the electrophysiology field by allowing physicians to perform cardiac ablation procedures in the growing number of interventional magnetic resonance (iCMR) suites found or being developed in leading hospitals.

In this episode, we are joined by Imricor’s Global Sales Leader, Greg Englehardt, to share the journey and their mission of bringing not just a set of innovative surgical tools to market, but also an entirely new operating environment! Where other larges companies have tried and failed, Greg details how the company has navigated an array of technical challenges to make their solution successful.

Between gaining Imricor’s CE mark approval and navigating a product launch during the pandemic, combined with Greg’s extensive experience with startups, this discussion is packed with insights. If you want to learn more about their upcoming US market development and how you could be part of a growing team then be sure to tune in so you can be informed and inspired.

Deep brain stimulation (DBS) is a neurosurgical procedure that treats neurological conditions by implanting electrodes into the brain to produce electrical impulses. These impulses can control abnormal brain activity and chemical imbalances that cause conditions like Parkinson's disease, essential tremor, and dystonia.

Despite the benefits of DBS, less than 1% of the 25 million patients who are eligible to undergo the procedure opt-in due to the invasiveness of and risk associated with traditional open brain surgery. Nicky Driscoll, CTO of NeuroBionics, joins this episode to share how their team is on a mission to change the status quo through bioelectronic medicine. NeuroBionics is developing devices that seamlessly integrate with the human body and aim to offer DBS with a minimally-invasive approach.

As well as learning about this exciting technology, Nicky shares insights into the journey from academic researcher to entrepreneur, and how they decided to focus on a challenging commercialization journey that could positively impact patient lives. As one of the top startups in the M2D2 accelerator program and recent winners of the 2024 Vision Award with Medtech Innovator, the NeuroBionics story is definitely one to follow, and is sure to leave you informed and inspired.

Amplitude Vascular Systems (AVS) is a medical device company based in Boston, MA, focused on safely and effectively treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital and Cue Growth Partners to develop their innovative Pulse IVL System that has recently received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its pivotal trial.

Angie Volk, VP of Business Development, and Sean Gilligan, COO of AVS, join this episode to share about their team’s mission and how they are bringing this exciting technology to market. With Johnson & Johnson’s $13.3B acquisition earlier this year of Shockwave Medical, the IVL space is showing that it is currently one of the hottest spaces in medtech. We discuss how AVS’s Pulse IVL System is being designed to easily deliver therapy across complex calcified lesions and reduce overall procedural costs, making it hugely attractive to potential future acquirers.

As former Boston Scientific colleagues, Angie and Sean have extensive industry experience including unique insights of building a winning culture, and they are leveraging these learnings and their network to efficiently navigate their solution to patients across the globe. With two medtech veterans, this is a conversation brimming with helpful tips for any would-be entrepreneur that is sure to leave you informed and inspired.